טוען...
Rho kinase inhibitors for treatment of glaucoma
Affecting 60 million patients, glaucoma is the second leading cause of blindness worldwide. Despite the availability of multiple medical and surgical treatments with effective intraocular pressure lowering, many patients still progress to become visually handicapped from glaucoma due to therapeutic...
שמור ב:
| הוצא לאור ב: | Expert Rev Ophthalmol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6319899/ https://ncbi.nlm.nih.gov/pubmed/30613208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/eop.11.65 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|